This study was carried out to investigate the potential effects of vitamin B12 and sitagliptin, and their possible synergistic effect with doxorubicin (DOX) on the Ehrlich solid tumor model. B12, sitagliptin, and their combination with DOX were administered to tumor‐bearing mice for 21 days. Treatment with B12, sitagliptin, as well as their combinations with DOX caused a significant inhibition of tumor growth and increased the survival time. Malondialdehyde levels and the relative expression of tumor necrosis factor‐α and nuclear factor kappa B were significantly decreased, whereas the total antioxidant capacity was significantly increased in all treated groups, except the DOX‐treated one, when compared with the positive control group. Moreover, increased apoptosis was also observed by increased cleaved caspase‐3 immunostaining and histopathological examination. In conclusion, the antitumor activity of B12 and sitagliptin could be attributed to their ability to induce apoptosis and suppress oxidative stress and inflammation.

中文翻译：

---

西他列汀和维生素B12对艾氏腹水癌实体瘤小鼠的抗肿瘤活性

进行这项研究以研究维生素B12和西他列汀的潜在作用，以及它们与阿霉素（DOX）可能对Ehrlich实体肿瘤模型产生的协同作用。将B12，西他列汀及其与DOX的组合给予荷瘤小鼠21天。B12，西他列汀及其与DOX的组合治疗可显着抑制肿瘤生长并延长生存时间。丙二醛水平以及肿瘤坏死因子α和核因子κB的相对表达均显着降低，而除DOX治疗组外，所有治疗组的总抗氧化能力均与阳性对照组相比显着增加。此外，通过裂解的caspase-3免疫染色和组织病理学检查还观察到凋亡增加。总之，B12和西他列汀的抗肿瘤活性可能归因于它们诱导凋亡，抑制氧化应激和炎症的能力。